2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Biological Processes, Apoptosis, Immune Mechanism, Microbiome, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

1794 EO2463 (EO) off-the-shelf peptide monotherapy in patients (pts) with previously untreated asymptomatic follicular (FL) and marginal zone (MZL) lymphoma: Impact of baseline factors (BLFs) and EO-induced expansion of specific CD8 T cells on clinical efficacy

Jose C Villasboas, MD, Reid W Merryman, MD2, Danielle Wallace, MD3, Stephen Douglas Smith, MD4, Jean Pierre Marolleau, PhD5, Luca Arcaini6, Carlos Grande Garcia, MD PhD7, Francesc Bosch, MD8, Antonio Pinto, MD9, Norma Gutiérrez, MD, PhD10, Brian G Till, MD11, Pierre Morel Sr, MD/PHD12, Sara Rattotti13, Maria Rocio Figueroa Mora14, Cristina García Herce, MD15, Jean-Marie Carpier16, Philippe Rinaudo17, Jan Fagerberg, MD, PhD18, Pier Luigi Zinzani, MD, PhD19, Stephen Maxted Ansell, MD, PhD20, Philippe Armand, MD21
1 Mayo Clinic, Rochester, Minnesota, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 University of Rochester, Rochester, New York, United States
4 Fred Hutchinson Cancer Center, University of Washington, Seattle, Washington, United States
5 Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France, Amiens, France
6 Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
7 Universidad de Navarra, Pamplona, Spain
8 University Hospital Vall d’Hebron, Barcelona, Spain
9 Fondazione 'G. Pascale', IRCCS, Naples, Italy
10 Hospital Universitario De Salamanca, IBSAL, Salamanca, Spain
11 Fred Hutchinson Cancer Center, University of Washington, Seattle, Washington, United States
12 Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France, Amiens, France
13 Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
14 Universidad de Navarra, Pamplona, Spain
15 University Hospital Vall d’Hebron, Barcelona, Spain
16 Enterome, Paris, France
17 Enterome, Paris, France
18 Enterome, Paris, France
19 University of Bologna, Bolgna, Italy
20 Mayo Clinic, Rochester, Minnesota, United States
21 Mayo Clinic, Rochester, Minnesota, United States

Background

EO is an immunotherapy designed to expand pre-existing memory CD8 T cells that recognize non-self-proteins from gut bacteria and cross-react with BCAs. EO includes 4 HLA-A2 epitopes with molecular mimicry to CD20, CD22, CD37, and BAFF-receptor, and the CD4-epitope UCP2. EO has a favorable safety profile (Blood 2025, 146, S1, 5377).

Methods

In trial EONHL1-20/SIDNEY (NCT04669171) EO was given subcutaneously with Montanide adjuvant to pts with HLA-A2, had untreated FL/MZL, and were not in need of standard treatment (watch-and-wait setting). Pts received EO (300µg/peptide) monotherapy q2 weekly (w) x4 then q4w x8 (39w).

Immune responses were tested on peripheral blood mononuclear cells without in vitro expansion by EO-mimic/BCA peptide-specific tetramers/flow cytometry, and expressed as sum % of CD8 T cells (among all peripheral CD8 T cells) specific for the 4 EO-mimic or 4 BCA peptides at a single timepoint.

Correlations between clinical efficacy and expansion of specific CD8 T cells were done in groups split at the median for max expansions (log-rank [LR]) and by groups with partial/complete response (PR/CR = objective response [OR]) vs no OR (investigator-assessed Lugano 2014 criteria; Mann-Whitney 2-sided tests [MW]).

Associations between 24 BLFs (related to patient, diagnosis, tumor burden, risk-scoring systems, and immune markers) and time-dependent efficacy outcomes  (duration of response [DOR], progression-free survival [PFS], time to next treatment [TTNT]), were analyzed by univariate analyses (LR) and for OR by Fisher’s exact 2-sided tests (FE). Associations between BLFs and expansion of specific CD8 T cells were analyzed by FE. The analyses were exploratory and hypothesis-generating; significance = p≤0.05 in BLFs with >3 pts/group considered; no adjustment for multiple testing.

Results

Among 25 pts efficacy evaluable (FL=22/MZL=3), 21 were evaluable for immune analyses (samples not assayed yet in 4 pts). EO-mimic and BCA peptide specific CD8 T cells were detected in 86% (95% CI 64-97) and 81% (95% CI 58-95) of pts; max median % at any time (in immune positive pts) were 0.67% (range 0.20-2.52) and 0.37% (range 0.08-1.10).

OR-rate was 40% (95% CI 21-61), with CR-rate 12% (95% CI 3-31); at a median follow-up of 9.8 months (mo) for progression the median DOR was not reached (only 2 progression events, remaining responders censored). At likewise short follow-up, median PFS was 17.0 mo (95% CI 9.6-NR) and median TTNT was 23.1 mo (95% CI 14.2-NR). 

Expansion after 1-2 doses of EO of BCA-specific CD8 T cells was higher for pts with PR/CR than for pts without PR/CR (MW p=0.032) and a high level of BCA-specific CD8 T cells at the same time was associated with a longer DOR (LR p=0.039). A higher level of EO-mimic specific CD8 T cells (at any time) associated with longer PFS (LR p=0.016) and TTNT (LR p=0.028).

None of the BLFs analyzed showed a consistent significant association with the level of EO-mimic and BCA peptide specific CD8 T cells; a single possible signal was found between lymphocyte-monocyte ratio (LMR)≤2 and lack of high level expansion of EO-mimic specific CD8 T cells (FE p=0.035).

None of the BLFs analyzed showed a significant association with achieving, or not, an OR, or DOR, on EO monotherapy. There were associations between shorter PFS and longer time from primary diagnosis until start EO (LR p=0.02) and for male gender (LR p=0.048). LMR≤2 (LR p=0.016) and high FLIPI-2 (LR p=0.017) were associated with shorter TTNT, while other immune markers (lymphocyte/CD4/CD8/B cell counts) and risk scoring systems (FLIPI, GELF, FLIPI24) did not show association with TTNT/PFS.  

Conclusions

EO monotherapy resulted in a PR/CR-rate of 40% in previously untreated pts with newly diagnosed FL/MZL in the watch-and-wait setting. High EO-induced expansion of specific CD8 T cells was associated with favorable outcomes across ORR, DOR, PFS, and TTNT.

No BLF was consistently associated with the level of EO-induced CD8 T cell expansion or OR/DOR suggesting that expansion occurred largely independently of baseline clinical and immune risk.

The consistency of these exploratory findings, indicating utility of EO across risk groups, supports the continued development of EO in the watch-and-wait setting of FL/MZL.

Jose C Villasboas, MD: Regeneron Pharmaceuticals, Inc. - Research Funding; Bristol Myers Squibb/Celgene - Research Funding; Genentech/Roche - Research Funding; Aptose Biosciences - Research Funding; Enterome - Research Funding; Epizyme - Research Funding; Kite/Gilead - Consultancy (Includes expert testimony); Curio Science - Consultancy (Includes expert testimony); TG Therapeutics - Consultancy (Includes expert testimony); Regeneron Pharmaceuticals, Inc. - Consultancy (Includes expert testimony)